Hikma, Celltrion Healthcare ink exclusive licensing agreement for Vegzelma for MENA markets
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company, for Vegzelma (CT-P16, bevacizumab). Under the terms of the agreement, Celltrion Healthcare will be responsible for the development, manufacturing and supply of Vegzelma and Hikma will be responsible for the commercialisation of the product in all its MENA markets, providing better access to a much needed oncology product. Vegzelma is a biosimilar to Avastin (bevacizumab) and is a US FDA and EMA approved anti-cancer monoclonal antibody treatment. The new agreement builds on Hikma
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
